Nash

INmune Bio, Inc. to Present at the BTIG Virtual Biotechnology Conference

Retrieved on: 
Thursday, August 5, 2021
Company, MD, Chief executive officer, Research, U.S. Securities and Exchange Commission, Inflammation, Limor Livnat, Tumor necrosis factor, Private Securities Litigation Reform Act, Patient, COVID-19, Natural killer cell, GLOBE, Cancer, Nash, Marketing, Conference, Nasdaq, Security (finance), Disease, Pharmaceutical industry

Please contact your representative at BTIG to schedule a virtual one-on-one meeting with INmune Bio during the respective conference.

Key Points: 
  • Please contact your representative at BTIG to schedule a virtual one-on-one meeting with INmune Bio during the respective conference.
  • is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
  • INmune Bios product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.
  • Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.

Enanta Pharmaceuticals Announces Nomination of Clinical Candidate EDP-235, its Lead Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19

Retrieved on: 
Thursday, August 5, 2021
Research, Infectious Diseases, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Fast Track, AbbVie, Research, U.S. Securities and Exchange Commission, Vaccine, Industry, Patent, Institute of Liver and Biliary Sciences, Fatty liver disease, Infection, Respiratory syncytial virus, Protease, Risk, Hepatitis B virus, Security (finance), RATS, Glecaprevir/pibrentasvir, Pharmacokinetics, HCV, Therapy, Degenerative disease, Severe acute respiratory syndrome coronavirus 2, RSV, Drug discovery, Human, Nash, Epithelium, Medication, Safety, Marketing, Nasdaq, HBV, Pharmaceutical industry

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the nomination of EDP-235, its lead oral protease inhibitor specifically designed for the treatment of COVID-19.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the nomination of EDP-235, its lead oral protease inhibitor specifically designed for the treatment of COVID-19.
  • As the virus continues to rapidly mutate, there remains a need for an oral, direct-acting antiviral that potently inhibits viral replication.
  • EDP-235 potently and selectively inhibits SARS-CoV-2 replication in multiple cellular models, including primary human airway epithelial cells, with an EC90 of 33nM.
  • Importantly, EDP-235 has excellent lung distribution in rats and demonstrates properties supportive of once daily oral dosing, in contrast to other protease inhibitors currently in development.

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

Retrieved on: 
Thursday, August 5, 2021
Fast Track, Clinical trial, Forward-looking statement, Population, Inflammation, Coronavirus, Annual report, Fibrosis, Non-alcoholic fatty liver disease, Patient, Perception, EMA, Armor (magazine), SEC, Liver cancer, Food and Drug Administration, Nash, Cirrhosis, Terminology, Drug development, Liver, Steatosis, Obesity, Physician, Risk, Cardiovascular disease, Pharmaceutical industry

The effect of Aramchol on fibrosis is mediated by downregulation of steatosis and directly on human collagen producing cells.

Key Points: 
  • The effect of Aramchol on fibrosis is mediated by downregulation of steatosis and directly on human collagen producing cells.
  • Aramchol has been granted Fast Track designation status by the FDA for the treatment of NASH.
  • It is the fastest growing cause of liver cancer and liver transplant in the U.S. due to the rise in obesity.
  • Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases.

Active Military Personnel, Law Enforcement Officers Eligible For Free Tickets To XFC 45/YoungGuns 3

Retrieved on: 
Thursday, August 5, 2021
Nash, The, DeltaPlex Arena, Military personnel, MI, UOL, Michigan State University, Mixed martial arts, RedeTV!, Television, OTC, HBO, Growth, NBCSN, Xtreme Fighting Championships, ID, ESPN, Detroit, Fox, Next Generation, Nightclub

To gain entry into the event, all active military personnel and law enforcement officers will have to show their ID or badge at the door, and they will be permitted to the action-packed XFC 45/YoungGuns 3 professional mixed martial arts showcase event.

Key Points: 
  • To gain entry into the event, all active military personnel and law enforcement officers will have to show their ID or badge at the door, and they will be permitted to the action-packed XFC 45/YoungGuns 3 professional mixed martial arts showcase event.
  • XFC President Myron Molotky: "The XFC has a proud tradition of honoring our military and those in law enforcement, and we're proud to once again do so with our biggest show yet, XFC 45/YoungGuns 3."
  • XFC CEO Steve Smith: "We're extremely grateful for those who serve our community, so we're once again thrilled to welcome military service people and law enforcement personnel free of charge on fight night as a token of our gratitude."
  • The XFC has had over 185 exclusively signed fighters, representing over 35+ countries worldwide with even more growth expected.

CohBar to Announce 2021 Second Quarter Financial Results and Provide Business Update on August 10, 2021

Retrieved on: 
Wednesday, August 4, 2021
Economy of New York City, Nasdaq, Finance

MENLO PARK, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today thatthe company will release its second quarter 2021 financial results after the market closes on Tuesday, August 10, 2021.

Key Points: 
  • MENLO PARK, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today thatthe company will release its second quarter 2021 financial results after the market closes on Tuesday, August 10, 2021.
  • ET (2:00 p.m. PT) on the same day to provide an update on the companys business.
  • Details for the Conference Call and Slide Presentation:
    Please visit https://us02web.zoom.us/j/84796437737?pwd=R2t0eEFRVDVlVDVZMTdhT0pGWVVsUT09 and enter password CWBR, or
    Go to www.cohbar.com and click on CohBar Q2 2021 Investor Presentation at the top of homepage.
  • An audio replay of the call will be available beginning at 8:00 p.m. Eastern Time on August 10, 2021, through 11:59 p.m. Eastern Time on August 31, 2021.

OliX Pharmaceuticals Announces Results from Preclinical Study of NASH Therapeutic Candidate

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, RNA, Biology, Biochemistry, Gene expression, Molecular biology, Small interfering RNA, RNA interference, N-Acetylgalactosamine

SUWON, Republic of Korea, Aug. 04, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today presented preclinical data on OLX702A, an investigational therapeutic for the treatment of nonalcoholic steatohepatitis (NASH), at the 48th Korean Academy of Science and Technology (KAST) International Symposium. In the study, OLX702A reversed tissue damage in the liver in a mouse model of NASH.

Key Points: 
  • In the study, OLX702A reversed tissue damage in the liver in a mouse model of NASH.
  • OLX702A is a GalNAc-conjugated asymmetric siRNA (asiRNA) that targets a novel gene which is validated as a NASH-related target based on a genome-wide association study (GWAS).
  • We look forward to progressing development of OLX702A based on these encouraging preclinical data, said Dong Ki Lee, Ph.D., founder and chief executive officer of OliX Pharmaceuticals.
  • OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study

Retrieved on: 
Monday, August 2, 2021
Health sciences, Health care, Life sciences, Adherence, Clinical pharmacology, Health care quality, Medical terminology, Pharmacy, Active ingredient

Aramchol meglumine contains the same active pharmaceutical ingredient (API) called Aramchol.

Key Points: 
  • Aramchol meglumine contains the same active pharmaceutical ingredient (API) called Aramchol.
  • Exposure with once daily (QD) 383mg Aramchol meglumine oral dosage corresponds to that obtained with the existing twice daily (BID) 300mg Aramchol free acid form which is currently being evaluated in the Phase 3 ARMOR study.
  • This allows future development of the QD regimen with a potential improvement in convenience and adherence".
  • Our lead compound, Aramchol, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.

LISCure Biosciences Announces Know-How License Agreement and Stock Purchase Agreement with Mayo Clinic

Retrieved on: 
Monday, August 2, 2021
Hepatitis, Mayo Clinic, Steatohepatitis, Mayo, Non-alcoholic fatty liver disease, Minnesota, States of the United States, Medicine

SEOUL, South Korea, Aug. 1, 2021 /PRNewswire/ -- LISCure Biosciences, Inc. ("LISCure") has entered into a know-how license and development collaboration agreement, and stock purchase agreement with Mayo Clinic to advance LISCure's microbiome therapeutics in non-alcoholic steatohepatitis (NASH).

Key Points: 
  • SEOUL, South Korea, Aug. 1, 2021 /PRNewswire/ -- LISCure Biosciences, Inc. ("LISCure") has entered into a know-how license and development collaboration agreement, and stock purchase agreement with Mayo Clinic to advance LISCure's microbiome therapeutics in non-alcoholic steatohepatitis (NASH).
  • Under the agreement, the company will receive Mayo Clinic's know-how to establish a new drug development of NASH program.
  • As part of the agreement, Mayo Clinic will become a shareholder in LISCure, the first Korean biotech company receiving equity investment from Mayo Clinic.
  • "We are also proud of Mayo Clinic becoming our shareholder and look forward to continuing a long-term collaboration."

Deargen Signs Agreement With Sookmyung Women’s University Research & Business Development Foundation for Licensing ‘NASH Biomarker’ Technologies

Retrieved on: 
Tuesday, July 27, 2021
Research, Pharmaceutical, Oncology, Data management, Technology, University, Genetics, Education, Science, Biotechnology, Other Technology, Health, Medical specialties, Clinical medicine, Hepatitis, Medicine, Sookmyung Women's University, Yongsan District, Non-alcoholic fatty liver disease, Steatohepatitis, Biomarkers, Nash

Deargen (President: Kilsoo Kang), an artificial intelligence (AI)-powered drug discovery and development company, announced on July 27 that it signed an agreement with Sookmyung Womens University Research & Business Development Foundation for licensing biomarker technologies for determining the progression stage of NASH (non-alcoholic steatohepatitis) patients.

Key Points: 
  • Deargen (President: Kilsoo Kang), an artificial intelligence (AI)-powered drug discovery and development company, announced on July 27 that it signed an agreement with Sookmyung Womens University Research & Business Development Foundation for licensing biomarker technologies for determining the progression stage of NASH (non-alcoholic steatohepatitis) patients.
  • View the full release here: https://www.businesswire.com/news/home/20210727005549/en/
    Deargen, an AI-powered drug discovery and development company, signed an agreement with Sookmyung Womens University Research & Business Development Foundation for licensing biomarker technologies for determining the progression stage of NASH (non-alcoholic steatohepatitis) patients.
  • (Graphic: Business Wire)
    Proprietary biomarker technologies licensed by Deargen from Sookmyung Womens University Research & Business Development Foundation can identify stages in patients with steatosis and NASH.
  • With the focus on clinical data in NASH patients and proprietary technologies of Sookmyung Womens University Research & Business Development Foundation that enables NASH patients to be distinguished by stages, we reached the technology transference agreement, said Kilsoo Kang, President of Deargen.

CohBar Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity

Retrieved on: 
Wednesday, July 14, 2021
Medical specialties, Hepatitis, Clinical medicine, Health care, Steatohepatitis, Non-alcoholic fatty liver disease, Nash

The process of data entry and final validation by the companys clinical research organization, which must be concluded prior to database lock, is ongoing.

Key Points: 
  • The process of data entry and final validation by the companys clinical research organization, which must be concluded prior to database lock, is ongoing.
  • CB4211 is a first-in-class mitochondria based therapeutic (MBT) that has demonstrated significant therapeutic potential in preclinical models of nonalcoholic steatohepatitis (NASH) and obesity.
  • NASH has been estimated to affect as many as 30 million adults in the U.S., and there is currently no approved treatment for the disease.
  • The companys lead compound, CB4211, is in the Phase 1b stage of a Phase 1a/1b clinical trial for nonalcoholic steatohepatitis (NASH) and obesity.